Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Angiotech Pharmaceuticals has received 510(k) clearance from the FDA to begin marketing sizes 3-0 and 4-0 of its Quill Self-Retaining System Polydioxanone product line.
Subscribe to our email newsletter
The Quill Self-Retaining System (SRS) Polydioxanone (PDO) is a longer-lasting absorbable suture, which is typically used for deeper tissue closures. These smaller diameter sizes incorporate a new design for better holding strength and expand the number and scope of procedures that can be done with the Quill SRS product.
William Hunter, president and CEO of Angiotech, said: “We are pleased to receive 510(k) approval for these new smaller diameter sizes. We intend to continue to broaden our Quill SRS product offering to cover multiple procedures for wound closure and tissue approximation.”